Abstract
Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7-15 |
| Number of pages | 9 |
| Journal | Disease of the Nervous System |
| Volume | 38 |
| Issue number | 12 II |
| State | Published - 1977 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Deanol in the management of involuntary movement disorders : A review. / Casey, Daniel.
In: Disease of the Nervous System, Vol. 38, No. 12 II, 1977, p. 7-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Deanol in the management of involuntary movement disorders
T2 - A review
AU - Casey, Daniel
PY - 1977
Y1 - 1977
N2 - Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.
AB - Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.
UR - http://www.scopus.com/inward/record.url?scp=0017762669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017762669&partnerID=8YFLogxK
M3 - Article
C2 - 145359
AN - SCOPUS:0017762669
VL - 38
SP - 7
EP - 15
JO - Disease of the Nervous System
JF - Disease of the Nervous System
IS - 12 II
ER -